- Home
- INFU vs SLS Comparison
INFU vs SLS Comparison
Compare INFU & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- SLS
- Stock Information
- Founded
- INFU 2005
- SLS 2012
- Country
- INFU United States
- SLS United States
- Employees
- INFU N/A
- SLS N/A
- Industry
- INFU Medical/Dental Instruments
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- INFU Health Care
- SLS Health Care
- Exchange
- INFU Nasdaq
- SLS Nasdaq
- Market Cap
- INFU 180.4M
- SLS 185.3M
- IPO Year
- INFU N/A
- SLS N/A
- Fundamental
- Price
- INFU $9.54
- SLS $1.91
- Analyst Decision
- INFU Strong Buy
- SLS Strong Buy
- Analyst Count
- INFU 1
- SLS 1
- Target Price
- INFU $12.00
- SLS $7.00
- AVG Volume (30 Days)
- INFU 272.3K
- SLS 1.8M
- Earning Date
- INFU 08-05-2025
- SLS 08-12-2025
- Dividend Yield
- INFU N/A
- SLS N/A
- EPS Growth
- INFU 2168.02
- SLS N/A
- EPS
- INFU 0.24
- SLS N/A
- Revenue
- INFU $139,886,000.00
- SLS N/A
- Revenue This Year
- INFU $11.06
- SLS N/A
- Revenue Next Year
- INFU $7.86
- SLS N/A
- P/E Ratio
- INFU $40.32
- SLS N/A
- Revenue Growth
- INFU 8.13
- SLS N/A
- 52 Week Low
- INFU $4.61
- SLS $0.77
- 52 Week High
- INFU $9.97
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- INFU 78.66
- SLS 60.77
- Support Level
- INFU $9.32
- SLS $1.50
- Resistance Level
- INFU $9.89
- SLS $1.77
- Average True Range (ATR)
- INFU 0.64
- SLS 0.11
- MACD
- INFU 0.13
- SLS 0.04
- Stochastic Oscillator
- INFU 90.58
- SLS 97.62
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.